Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00140348 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine
A Phase 1 study of Prostate Cancer, sponsored by Cell Genesys.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 12
- Study locations
NCT00140348: Completed Phase 1 study of Prostate Cancer, sponsored by Cell Genesys.
NCT00140348 is a Phase 1 study of Prostate Cancer that has completed, run by Cell Genesys. The registered enrollment target is 80 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00140348, a Phase 1 study of Prostate Cancer, has completed, sponsored by Cell Genesys.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to evaluate clinical and laboratory safety in patients receiving 4 different doses of GVAX® Prostate Cancer Vaccine in order to determine a maximum tolerated dose.
Conditions Studied
Interventions
- BIOLOGICAL Immunotherapy allogeneic GM-CSF secreting cellular vaccine
Study Locations (12)
California
- South Orange County Medical Research Center - Laguna Woods
- UCSF - San Francisco
- West Coast Clinical Research - Tarzana
Washington
- Virginia Mason Med. Crt. - Seattle
- Seattle Cancer Care Alliance - Seattle
Florida
- South Florida Medical Research - Aventura
Georgia
- Emory University - Atlanta
Illinois
- Carle Cancer Center - Urbana
Indiana
- Northeast Indiana Research - Fort Wayne
Michigan
- University of Michigan Medical Center - Ann Arbor
Pennsylvania
- Fox Chase cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2001-12 |
| Est. Completion | 2005-04 |
| Phase | Phase 1 |
What the finished NCT00140348 record still lists
NCT00140348 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Immunotherapy allogeneic GM-CSF secreting cellular vaccine is the first listed.
NCT00140348 lists 12 locations in 9 states (California, Washington, Florida).
Frequently Asked Questions
What is clinical trial NCT00140348 about?
NCT00140348 is a clinical study titled "Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine". The purpose of this study is to evaluate clinical and laboratory safety in patients receiving 4 different doses of GVAX® Prostate Cancer Vaccine in order to determine a maximum tolerated dose.
What is the current status of trial NCT00140348?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2001-12. Estimated completion is 2005-04.
What conditions does trial NCT00140348 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00140348?
The interventions under investigation include: Immunotherapy allogeneic GM-CSF secreting cellular vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00140348?
This trial is sponsored by Cell Genesys, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00140348 being conducted?
This trial has 12 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00140348's enrollment target sits among peer trials
80 370th of 735 higher than 355 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia